<DOC>
	<DOC>NCT02092207</DOC>
	<brief_summary>This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).</brief_summary>
	<brief_title>Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Corneal staining score of ≥5 in either eye by the National Eye Institute/Industry Workshop guidelines Schirmer test score (without anesthesia) &lt; 7 mm/5 min in either eye Willing to use no topical ocular treatments, other than REFRESH TEARS® for the duration of the trial Intraocular surgery within 3months Persistent intraocular inflammation or infection Corneal transplantation or neurotrophic keratitis StevensJohnson Syndrome Ocular herpes simplex virus infection Concomitant use of contact lenses or use within 3months Silicone lacrimal punctal occlusion or cauterization of the punctum within 3months Vision correction surgery without DES within 12months Unstable use of methotrexate or Diseasemodifying drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>